SNOA

Sonoma Pharmaceuticals, Inc. Common Stock

SNOA
Closed
$1.26
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Country

US

CEO

Ms. Amy Trombly

IPO date

2007

Employees

8

ISIN

US83558L3033

Key stats

Open

$1.26

Volume

115.76K

Market cap

$5.93M

Prev. close

$1.26

Impl / hst vl

-

Open interest

$0.00

$1.25

Day’s Range

$1.31

$0.85

52W Range

$3.89

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
0.30
P/B
1.89
Current ratio
2.50
Debt / Equity
-0.70
ROE
-88.38%
Gross margin
39.22%
Income growth
-29.06%
FCF growth
-32.43

Analysts estimates

Consensus rating
Strong buy

The average rating from top 3 analysts indicates that stock may significantly outperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$15.10
The top 3 analysts forecasts that 12-month price may increase by 1,098.10%, with a low of $14.95 and a high of $15.54
$14.95
Low
$15.10
Avg
$15.54
High
Current price

Earnings

Q1 ‘26 revenue
$5.56M
Q1 ‘26 net income
-$581.00K
Revenue
Net income
Previous EPS
-$0.32
Estimate EPS
-$0.31
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply